Springer Nature and the GlomCon Foundation Announce Launch of Open Access Journal, Rare Kidney Diseases
Springer Nature partners with the GlomCon Foundation to make rare kidney disease research accessible to the global community.
New York | 27 January 2026
Springer Nature has been chosen as the publishing partner for the GlomCon Foundation's fully Open Access (OA) journal, Rare Kidney Diseases. The GlomCon Foundation, a non-profit consortium for clinicians and experts dedicated to advancing rare kidney disease education and research, is expected to begin accepting submissions to the journal in early 2026.
This new peer-reviewed journal will serve as a global platform dedicated to advancing research, clinical practice, and innovation in rare and complex kidney diseases. Rare Kidney Diseases will publish reviews, editorials, clinical insights, controversies, pathology correlations, methodological advances, and novel artificial intelligence applications relevant to rare kidney diseases.
Dr. Ali Poyan Mehr, Founding President of GlomCon Foundation, and Dr. Andreas Kronbichler, inaugural Editor-in-Chief of Rare Kidney Diseases, said: "This partnership reflects GlomCon's commitment to continuing to invest in research for rare kidney diseases and improving the lives of patients. This collaboration with Springer Nature and the GlomCon Foundation will establish an impactful journal exploring new diagnostic and therapeutic approaches in kidney diseases."
Jason Winkler, Vice President, Medicine & Life Sciences Journals for Springer Nature stated: "We are excited to partner with the GlomCon Foundation on the launch of their open access journal, through which we will expand access to the research that scientists and clinicians need to advance the health and wellbeing of patients around the world."
More information can be found on Rare Kidney Diseases can be found here. More information about Springer Nature’s partnerships with societies can be found here, and its commitment and progress as a publisher in its Annual Progress, Sustainable business and OA reports.
Springer Nature is one of the leading publishers of research in the world. We publish the largest number of journals and books and are a pioneer in open research. Through our leading brands, trusted for more than 180 years, we provide technology-enabled products, platforms and services that help researchers to uncover new ideas and share their discoveries, health professionals to stay at the forefront of medical science, and educators to advance learning. We are proud to be part of progress, working together with the communities we serve to share knowledge and bring greater understanding to the world. For more information, please visit about.springernature.com and @SpringerNature.
The GlomCon Foundation brings together clinicians, pathologists, researchers, and biotech innovators to create a scalable network of stakeholders interested in helping patients with glomerular kidney disease. Through this network of collaborations, GlomCon aims to make the collective expertise of its members available for discussion of individual cases, provide infrastructure for biomarker studies, enable genomic research, and facilitate clinical trials.
For more information, visit https://www.glomcon.org/.
Eseohe Arhebamen-Yamasaki | Head of Communications, U.S. | Springer Nature
eseohe.yamasaki@springernature.com
